Dartmouth scientists have discovered two human genes encoding nicotinamide riboside kinases that are highly specific for activation of a class of anti-cancer, anti-viral and immunosuppressive prodrugs related to tiazofurin. These genes and their encoded enzymes are useful for drug development and for identifying patients who may be susceptible to treatment with a prodrug related to tiazofurin.
These findings are claimed in the published United States Patent Application Nos. 11/542,832, 11/912,400, and 12/411,586 as well as several pending and published foreign applications. We are seeking an industrial partner to further refine and market this technology. (Ref: J263)
